Table 4.
GP biomarker candidates in studies included in the systematic review of IBD
| Author (year) | IBD type | Sample | GP biomarker candidate | Additional description |
|---|---|---|---|---|
| Iwatani et al. (2020) | CD | Plasma | PSa 40:3, PSa 38:3, PSa 42:4 | |
| LPS 18:0 | ||||
| Horta et al. (2021) | CD | Plasma | PI 14:0/18:1 | GP biomarker candidates having odd carbon number of fatty acid chain are excluded. |
| LPI 16:0, LPI 18:0, LPI 18:1 | ||||
| PC 10:0/26:2, PC 12:0/22:2, PC 12:0/24:2, PC 14:1/22:4, PC 16:1/16:0, PC 14:0/14:0, PC 14:0/16:0, PC 16:0/18:1, PC 18:1/18:0 | FA biomarker candidates in the 50 most discriminant biomarkers. | |||
| LPC 16:0 | ||||
| Plasmenyl PC P-14:0, Plasmenyl PC P-20:0 | ||||
| Plasmenyl PC O-18:0, Plasmenyl PC O-20:0 | ||||
| Plasmenyl PE P-18:0 | ||||
| PE-NMe2 16:0/16:0 | ||||
| PS 10:0/18:0 | ||||
| PA 16:0/26:2 | ||||
| Methyl PA 14:0/20:2 | ||||
| Guan et al. (2020) | CD/UC | Plasma | LPA 18:2 | |
| LPC 20:4, LPC 22:1, LPC 24:1 | ||||
| Daniluk et al. (2019) | CD/UC | Serum | PC 36:6, PC 16:0/20:3, PC 16:0/20:4 | GP biomarker candidates having odd carbon number of fatty acid chain are excluded. |
| LPC 14:0 (sn-1, sn-2), LPC 16:0, LPC 16:1 (sn-1, sn-2), LPC 18:1 (sn-1, sn-2), LPC 18:2 (sn-1, sn-2), LPC 18:3, LPC 20:0, LPC 20:2, LPC 20:3, LPC 20:4, LPC 20:5, LPC 22:4, LPC 22:5, LPC 22:6 | ||||
| LPA 18:2, LPA 20:4 | ||||
| Diab et al. (2019) | UC | Tissue | PE 38:3 | |
| Fan et al. (2015) | CD/UC | Plasma | Alkylphosphatidylcholine | Lysoalkylphosphatidylcholine, alkenylphosphatidylethanolamine, phosphatidylserine subclass were relatively significant only between CD versus control group. |
| Alkenylphosphatidylcholine | ||||
| Lysoalkylphosphatidylcholine | ||||
| Alkylphosphatidylethanolamine | ||||
| Alkenylphosphatidylethanolamine | ||||
| Phosphatidylserine | ||||
| Bazarganipour et al. (2019) | UC | Plasma | LPC 16:0, LPC 18:1, LPC 18:2, LPC 18:3, LPC 20:0, LPC 24:0 | Although lipidomic analysis was done by using both plasma and tissue samples, GP subclass was revealed only in plasma samples. |
| LPE 18:1, LPE 18:2 | ||||
| Murgia et al. (2018) | CD | Plasma | PC 32:1, PC 34:1, PC 34:2, PC 34:3, PC 36:1, PC 36:2, PC 36:3, PC 36:4, PC 38:3, PC 38:5, PC 38:6, PC 38:7, PC 40:6 | |
| LPC 16:0, LPC 18:0, LPC 18:1, LPC 18:2 | ||||
| Ehehalt et al. (2004) | CD | Tissue | PC 34:1, PC 34:2, PC 36:1, PC 36:2 | |
| LPC 16:0, LPC 18:0 | ||||
| Braun et al. (2009) | CD/UC | Ileal Mucus Tissue | PC 32:0, PC 34:2 | PC 34:2 can discriminate only between UC versus control. |
| Colonic Mucus Tissue | PC 32:0, PC 34:2, PC 36:1, PC 36:2, PC 36:4 | PC 36:2, 36:4 can discriminate only between UC versus control. | ||
| Tefas et al. (2020) | CD | Serum | LPE 22:6, LPE 24:6 | |
| LPC 18:2, LPC 20:4, LPC 22:6 | ||||
| Sewell et al. (2012) | CD | Tissue | PI 16:0/18:1 | The proportion of significant PC were increased in CD group stimulated with heat-killed Escherichia coli. |
| Cell | PC 16:0/20:4 |